SAB Biotherapeutics appoints Lucy To as CFO effective August 12, 2024

SAB Biotherapeutics, Inc.

Lucy To appointed CFO; Mark Conley reassumes VP Finance role effective August 12.
To brings 18+ years experience; most recently MD at Wells Fargo Healthcare IB.
Employment agreement: $475K base, $125K signing bonus, 125K stock options vesting over 4 years.
Top-line Phase 1 data for T1D drug SAB-142 expected by end of 2024 per press release.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lucy To

Chief Financial Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2024-08-12
Filed: July 31, 2024, 7:59 PM ET

On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.

Role change

Mark Conley

Vice President of Finance

SABS · SAB Biotherapeutics, Inc.

Effective: 2024-08-12
Filed: July 31, 2024, 7:59 PM ET

Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lucy To was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Mark Conley changed role as Vice President of Finance at SAB Biotherapeutics, Inc..

Action: reassume
Role: Vice President of Finance

Exact text from the filing

Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-088247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.